Search
New York Paid Clinical Trials
A listing of 4481 clinical trials in New York actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
25 - 36 of 4481
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
New York is currently home to 4481 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Recruiting
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
07/17/2025
Locations: Integrative Clinical Trials LLC, Brooklyn, New York
Conditions: Depressive Disorder, Major
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Recruiting
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Multiple Myeloma
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
07/17/2025
Locations: Neurological Associates of Albany, PC, Albany, New York
Conditions: Preclinical Alzheimer's Disease
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
Recruiting
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Icahn School of Medicine at Mt. Sinai, New York, New York
Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
Recruiting
The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/17/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Atrial Fibrillation
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/17/2025
Locations: Albany Medical College, Division of Community Endocrinology, Albany, New York
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Recruiting
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Integrated Medical Professionals, New York, New York
Conditions: Non-Muscle Invasive Bladder Cancer
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Recruiting
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without a KMT2A gene rearrangement (KMT2A-germline \[G\]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoc... Read More
Gender:
ALL
Ages:
365 days and below
Trial Updated:
07/17/2025
Locations: Albany Medical Center, Albany, New York
Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Recruiting
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: NYU Langone Health, New York, New York
Conditions: Advanced Solid Tumors
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Recruiting
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/17/2025
Locations: NYU Langone Health, New York, New York
Conditions: Pulmonary Arterial Hypertension
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/17/2025
Locations: NYU Langone Health, Lake Success, New York
Conditions: Colitis, Ulcerative
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Recruiting
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
25 - 36 of 4481
When investigators decide to start a clinical trial, regulatory agencies such as the FDA and the IRB must review all plans and protocols to determine if the proposed trial is safe, ethical, and feasible. All clinical trials that recruit human participants have been reviewed and approved, and both non-paid and paid clinical research studies exist in New York.
After the study is approved the research team sets out to recruit volunteers who would like to participate in a clinical trial. Usually, volunteers are compensated for their time and travel expenses, and many paid clinical trials exist.
While one of the purposes of conducting clinical trials is testing the intervention on a large sample that would be representative of the general population, studies often have inclusion and exclusion criteria that outline who can and cannot participate. The inclusion criteria specifies the characteristics a participant must have in order to participate; for example, a liver cancer trial may have as an inclusion criteria that the participant must be a liver cancer patient.
On the other hand, the exclusion criteria outlines what type of individuals cannot participate; for example, a clinical trial testing a vitamin supplement in healthy individuals might want to disqualify participants who suffer from a serious condition and that can jeopardize the participant's ability to safely receive the experimental intervention. Due to safety concerns, pregnancy is often an exclusion criteria found in many studies.
In New York State, Columbia University and Mount Sinai Hospital are two of the largest research centers conducting clinical trials on a regular basis. As of this month, Columbia University is actively recruiting participants on at least 200 clinical trials from all phases, and Mount Sinai has over 500 active clinical trials.
Search Clinical Trials in New York by Condition
See All Conditions